Citius Pharmaceuticals (CTXR) Cash from Operations (2010 - 2026)

Citius Pharmaceuticals (CTXR) has reported Cash from Operations for 17 consecutive years, with -$8.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 60.75% year-over-year to -$8.7 million; the trailing twelve-month figure through Jun 2026 stood at -$34.9 million (down 69.45% YoY), and the FY2025 full-year result was -$26.6 million, up 5.85% from the prior year.
• Cash from Operations retreated to -$8.7 million in Q2 2026 per CTXR's latest filing, from -$1.3 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$1.3 million in Q1 2026 and bottomed at -$13.0 million in Q4 2025.
• Historically, Cash from Operations has averaged -$7.3 million across 5 years, with a median of -$7.3 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Cash from Operations tumbled 175.27% in 2025, then surged 71.36% in 2026.
• Over 5 years, Cash from Operations stood at -$4.8 million in 2022, then slipped by 27.17% to -$6.1 million in 2023, then climbed by 22.97% to -$4.7 million in 2024, then sank by 175.27% to -$13.0 million in 2025, then soared by 33.19% to -$8.7 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$8.7 million, -$1.3 million, and -$13.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.